<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="EN" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Med.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Medicine</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Med.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2296-858X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fmed.2026.1734619</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>ESRP1 drives epithelial-mesenchymal transition by activating EPAC-RAP1A signaling axis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Qi</surname> <given-names>Ruixin</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/2772867/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname> <given-names>Jiaqi</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Cheng</surname> <given-names>Guocang</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhao</surname> <given-names>Tingting</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Hu</surname> <given-names>Zhengyu</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Yu</surname> <given-names>Jialin</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Jia</surname> <given-names>Yuanyuan</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c002"><sup>&#x002A;</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Chen</surname> <given-names>Juan</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="corresp" rid="c003"><sup>&#x002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1686197/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Ningxia Key Laboratory of Clinical and Pathogenic Microorganisms, Institute of Medical Science, General Hospital of Ningxia Medical University</institution>, <city>Yinchuan</city>, <country country="cn">China</country></aff>
<aff id="aff2"><label>2</label><institution>Department of Respiratory and Critical Care Medicine, Qingyang People&#x2019;s Hospital, Qingyang</institution>, <city>Gansu</city>, <country country="cn">China</country></aff>
<aff id="aff3"><label>3</label><institution>Department of Respiratory and Critical Care Medicine, General Hospital of Ningxia Medical University</institution>, <city>Yinchuan</city>, <country country="cn">China</country></aff>
<author-notes>
<corresp id="c001"><label>&#x002A;</label>Correspondence: Jialin Yu, <email xlink:href="mailto:aries6687@163.com">aries6687@163.com</email></corresp>
<corresp id="c002">Yuanyuan Jia, <email xlink:href="mailto:1249866576@qq.com">1249866576@qq.com</email></corresp>
<corresp id="c003">Juan Chen, <email xlink:href="mailto:chenjuan7419@163.com">chenjuan7419@163.com</email></corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-02-06">
<day>06</day>
<month>02</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2026</year>
</pub-date>
<volume>13</volume>
<elocation-id>1734619</elocation-id>
<history>
<date date-type="received">
<day>29</day>
<month>10</month>
<year>2025</year>
</date>
<date date-type="rev-recd">
<day>02</day>
<month>01</month>
<year>2026</year>
</date>
<date date-type="accepted">
<day>02</day>
<month>01</month>
<year>2026</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2026 Qi, Wang, Cheng, Zhao, Hu, Yu, Jia and Chen.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Qi, Wang, Cheng, Zhao, Hu, Yu, Jia and Chen</copyright-holder>
<license>
<ali:license_ref start_date="2026-02-06">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease characterized by epithelial-mesenchymal transition (EMT) as a key pathological feature. The molecular mechanism of EMT is not fully understood. Hence, the current study aimed to investigate the pathogenesis of EMT, which focus on the function of Epithelial Splicing Regulatory Protein 1 (ESRP1) in regulating EMT.</p>
</sec>
<sec>
<title>Methods</title>
<p>The present study utilized bleomycin (BLM) to establish mouse models of IPF. Then, single-cell RNA sequencing (scRNA-seq) of entire lung tissue was employed to delineate transcriptional alterations in epithelial cells and to nominate prospective regulators of EMT. The target gene was subsequently validated <italic>in vivo</italic> and <italic>in vitro</italic> by qPCR, western blot, and immunofluorescence. Furthermore, an EMT model was established in TGF-&#x03B2;1&#x2013;treated MLE-12 alveolar epithelial cells. Lentivirus or siRNA was hired to modulate the expression of target gene and elucidate its mechanistic contribution to EMT.</p>
</sec>
<sec>
<title>Results</title>
<p>ScRNA-seq revealed marked up-regulation of the ESRP1 in alveolar epithelial cells compared with PBS-treated controls. Subsequent mechanistic interrogation in primary and MLE-12 alveolar epithelial cells demonstrated that knockdown of ESRP1 suppressed, whereas its overexpression potentiated, the expression of Epac, Rap1a, and N-cad which were key effectors of EMT. Importantly, Co-IP (Co-Immunoprecipitation) showed that there was interaction between ESRP1, Epac, and Rap1a. Silencing of either Epac or Rap1a did not reciprocally alter ESRP1 expression, confirming an upstream regulatory hierarchy.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>Our findings demonstrate that ESRP1 upregulation in alveolar epithelial cells drives IPF progression by promoting EMT via the Epac&#x2013;Rap1a axis.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Epac-Rap1a signaling</kwd>
<kwd>epithelial</kwd>
<kwd>epithelial splicing regulatory protein 1 (ESRP1)</kwd>
<kwd>epithelial-mesenchymal transition (EMT)</kwd>
<kwd>idiopathic pulmonary fibrosis</kwd>
<kwd>single-cell RNA sequencing (scRNA-seq)</kwd>
</kwd-group>
<funding-group>
<award-group id="gs1">
<funding-source id="sp1">
<institution-wrap>
<institution>National Natural Science Foundation of China</institution>
<institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100001809</institution-id>
</institution-wrap>
</funding-source>
</award-group>
<funding-statement>The author(s) declared that financial support was received for this work and/or its publication. This work was funded by the National Natural Science Foundation of China (No. 82460200), Special Project of Central Government Guiding Local Science and Technology Development of Ningxia (No. 2024FRD05046), Key Research and Development Project of Ningxia (No.2023BEG02021 and No. 2025BEG02002), and National Science and Technology Major Project of China (No. 2024ZD0528905).</funding-statement>
</funding-group>
<counts>
<fig-count count="6"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="37"/>
<page-count count="15"/>
<word-count count="7783"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Pulmonary Medicine</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Idiopathic pulmonary fibrosis (IPF), a progressive and fatal interstitial lung disease, manifests through fibroblast hyperproliferation, pathological extracellular matrix (ECM) deposition, and irreversible lung function decline (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). Despite FDA-approved therapies (pirfenidone/nintedanib), clinical outcomes remain suboptimal with marginal survival benefits (<xref ref-type="bibr" rid="B3">3</xref>&#x2013;<xref ref-type="bibr" rid="B5">5</xref>), underscoring an urgent need to elucidate molecular drivers of fibrosis, particularly epithelial-mesenchymal transition (EMT), a cornerstone of IPF pathogenesis (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>). In IPF, alveolar epithelial injury triggers TGF-&#x03B2;1-dominated EMT, transforming epithelial cells into collagen-secreting myofibroblasts via Smad/MAPK pathways (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>). This process is defined by E-cadherin (E-cad)/ZO-1(Zonula Occludens-1) suppression and &#x03B1;-SMA (alpha-Smooth Muscle Actin)/Vimentin (Vim) induction (<xref ref-type="bibr" rid="B10">10</xref>&#x2013;<xref ref-type="bibr" rid="B12">12</xref>), yet upstream regulators orchestrating EMT initiation remain poorly defined.</p>
<p>In this research, we established murine IPF model, and single-cell RNA sequencing revealed marked up-regulation of ESRP1 in epithelial cells. According to previous study, ESRP1, an RNA-binding protein restricted to epithelial lineages, orchestrates the alternative splicing of multiple transcripts that regulate cell&#x2013;cell adhesion, motile behavior, and intracellular signaling cascades (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>). While ESRP1&#x2019;s tumor-suppressive or oncogenic roles has been well-documented (<xref ref-type="bibr" rid="B15">15</xref>&#x2013;<xref ref-type="bibr" rid="B21">21</xref>), its function in IPF is poorly characterized. Growing evidence demonstrated that ESRP1 orchestrates the alternative splicing of multiple transcripts, including bFGF (basic Fibroblast Growth Factor), FGFR2 (Fibroblast Growth Factor Receptor 2), CD44 (Cluster of Differentiation 44), CTNND1 (Catenin Delta 1/p120-catenin) and ENAH (Enabled Homolog), thereby modulating epithelial plasticity and migratory capacity (<xref ref-type="bibr" rid="B22">22</xref>&#x2013;<xref ref-type="bibr" rid="B27">27</xref>). A recent study also implicates an ESRP1-mediated circRNA network in TGF-&#x03B2;1-driven EMT in breast cancer (<xref ref-type="bibr" rid="B28">28</xref>).</p>
<p>Hence, the current study aimed to investigate the roles of ESRP1 in IPF-associated EMT. We first established mouse model of Bleomycin (BLM)-induced IPF and subjected to scRNA-seq. ESRP1 exhibited the most pronounced up-regulation within injured alveolar epithelial cells. Both experimental models and clinical investigations have shown that ESRP1 exhibits elevated expression in the lungs of individuals with IPF as well as in BLM-treated mouse lungs. Furthermore, spatial immunoprofiling revealed co-induction of ESRP1 with Epac and Rap1a across fibrotic lungs. In MLE-12 cells, knockdown or overexpression of <italic>esrp1</italic> elicited concordant changes in Epac (Exchange Protein directly Activated by cAMP), Rap1a (Ras-related Protein 1a), and N-cad (N-cadherin), whereas silencing of <italic>epac</italic> or <italic>rap1a</italic> left ESRP1 expression unaltered. Co-IP showed that there was interaction between ESRP1, Epac and Rap1a. To date, ESRP1 acts as an upstream gatekeeper that licenses EMT via the Epac&#x2013;Rap1a axis and represents a tractable therapeutic target for EMT-driven fibrosis in IPF.</p>
</sec>
<sec id="S2" sec-type="results">
<label>2</label>
<title>Results</title>
<sec id="S2.SS1">
<label>2.1</label>
<title>Single cell sequencing showed that ESRP1 was highly expressed in epithelial cells of BLM-induced lung fibrosis mouse model</title>
<p>At the start of the experiment (day 0), male C57BL/6J mice aged 6&#x2013;8 weeks received one intratracheal instillation of BLM at 2 mg/kg, prepared in 50 &#x03BC;L sterile saline. Mice were then monitored for 21 days under SPF housing conditions and euthanized on day 21 for tissue collection and subsequent analyses. After 21 days of BLM treatment, BLM exposure resulted in evident histopathological alterations, as shown by H&#x0026;E staining, including inflammatory cell infiltration, alveolar enlargement, and septal thickening. Extensive collagen deposition was observed in the tissue sections when examined by Masson&#x2019;s trichrome staining, primarily localized around bronchioles and within the alveolar interstitium. IHC (Immunohistochemistry) further confirmed elevated expression of Fn1(Fibronectin) (<italic>P</italic> &#x003C; 0.001), Vim (<italic>P</italic> &#x003C; 0.001), and &#x03B1;-SMA (<italic>P</italic> &#x003C; 0.001), indicating enhanced fibrotic activity in BLM-treated lungs (<xref ref-type="supplementary-material" rid="FS1">Supplementary Figure 1a</xref>). The impact of BLM and normal saline on mouse body weight was monitored over time. In the BLM-treated group, weight gain ceased by day 14, followed by a more pronounced reduction in body weight observed on day 21, indicating progressive systemic effects associated with fibrosis induction (<xref ref-type="supplementary-material" rid="FS1">Supplementary Figure 1b</xref>). Hydroxyproline assays of lung homogenates demonstrated significantly higher collagen content in the BLM-treated group compared to controls, supporting increased extracellular matrix deposition (<xref ref-type="supplementary-material" rid="FS1">Supplementary Figure 1c</xref>). Western blot and qPCR analyses showed significant upregulation of fibrosis-related markers, including Fn1, N-cad, &#x03B1;-SMA, and Zeb1 (Zinc Finger E-box Binding Homeobox 1), in lungs from bleomycin-treated mice, relative to controls, at the gene and protein expression levels (<italic>P</italic> &#x003C; 0.05) (<xref ref-type="supplementary-material" rid="FS1">Supplementary Figure 1d</xref>). Our data confirm that BLM-treatment reliably produced a model of pulmonary fibrosis, distinguished by extensive inflammatory infiltration and tissue injury. While ESRP1 is well-known for regulating FGFR2 alternative splicing, which we confirmed via qPCR (<xref ref-type="supplementary-material" rid="FS1">Supplementary Figure 1e</xref>). This alteration did not fully account for the observed fibrotic phenotype. The primers used for this study are summarized in <xref ref-type="table" rid="T1">Table 1</xref>. Further mechanistic exploration identified the Epac-Rap1a pathway as the predominant mediator through which ESRP1 exerts its pro-EMT effects in this specific context.</p>
<table-wrap position="float" id="T1">
<label>TABLE 1</label>
<caption><p><italic>FGFR2-IIIb</italic> and <italic>FGFR2-IIIc</italic> sequence used in this study (Sangon Biotech).</p></caption>
<table cellspacing="5" cellpadding="5" frame="box" rules="all">
<thead>
<tr>
<th valign="top" align="left">Gene name</th>
<th valign="top" align="left">Sense</th>
<th valign="top" align="left">AntiSense</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left"><italic>FGFR2-IIIb</italic></td>
<td valign="top" align="left">CAACACCGAGAAGAT<break/>GGAGAAG</td>
<td valign="top" align="left">CACCATGCAGGCGATTAA<break/>GA</td>
</tr>
<tr>
<td valign="top" align="left"><italic>FGFR2-IIIc</italic></td>
<td valign="top" align="left">CCAGCACTGGAGCCTT<break/>ATTAT</td>
<td valign="top" align="left">GATCCTCTGGCAACTCAT<break/>ACTC</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p><italic>FGFR2-IIIb</italic> and <italic>FGFR2-IIIc</italic>, alternative splicing isoforms of Fibroblast Growth Factor Receptor 2.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Furthermore, to explore the cellular heterogeneity in the BLM-induced IPF model, we performed sc-RNA seq of lung tissues collected on day 21 post-treatment from both BLM and PBS groups (<xref ref-type="fig" rid="F1">Figure 1a</xref>). After quality control, we profiled 91,418 cells from total lung samples obtained from 3 PBS control mice and 3 BLM treatment mice, identified 10 discrete cell types based on distinct markers, cells were visualized using UMAP (Uniform Manifold Approximation and Projection) projection and grouped into 10 major cell populations based on canonical marker genes (<xref ref-type="fig" rid="F1">Figure 1b</xref>). The identified clusters included: Monocyte_Macrophage, B cells, T/NK cells, Neutrophils, Dendritic Cells (DCs), Fibroblasts, Myofibroblast-like cells, Epithelial cells, Endothelial cells, and Basophils.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption><p>Single-cell landscape of cellular composition in bleomycin-induced pulmonary fibrosis. <bold>(a)</bold> Flow chart of single cell sequencing. <bold>(b)</bold> UMAP plots showing the distribution of lung cell populations from BLMd21 and PBSd21 mice. A total of 10 major cell types were identified and annotated based on canonical markers: Monocyte_Macrophage (red), B cells (green), T/NK cells (yellow), Neutrophils (blue), Endothelial cells (orange), Dendritic cells (DC, pink), Fibroblasts (cyan), Myofibroblast-like cells (purple), Epithelial cells (light green), and Basophils (brown). Color indicates cluster identity. <bold>(c)</bold> Violin plots illustrate the expression profiles of representative marker genes across the annotated cell populations. The <italic>X</italic>-axis represents the top genes for each cell subgroup, while the <italic>Y</italic>-axis denotes the different cell types. <bold>(d)</bold> Bar plot showing the proportional distribution of each cell type between BLM and PBS groups. Notably, fibrotic lungs displayed increased fibroblast and myofibroblast-like populations, with a concomitant reduction in epithelial cells. <bold>(e)</bold> Quantification of epithelial cell proportion (percentage of total cells) showed a decreasing trend in the BLM group compared to PBS, though without statistical significance (ns, unpaired <italic>t</italic>-test).</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmed-13-1734619-g001.tif">
<alt-text content-type="machine-generated">Diagram illustrating an experimental workflow and data analysis. Panel A shows a timeline for BLM/PBS administration in mice, with sample collection for single-cell RNA sequencing and subsequent data analysis. Panel B displays UMAP plots of cell populations, color-coded by type, comparing BLM and PBS treatments. Panel C is a violin plot showing gene expression levels across different cell types. Panel D is a bar graph depicting the proportion of various cell types in BLM and PBS samples. Panel E shows a bar graph comparing the percentage of total cells in PBS versus BLM, highlighting a non-significant difference.</alt-text>
</graphic>
</fig>
<p>Top marker genes for each cell type were identified via differential expression analysis and visualized in violin plots (<xref ref-type="fig" rid="F1">Figure 1c</xref>). For example, Col1a1 (Collagen Type I Alpha 1) and Acta2 (Actin Alpha 2, Smooth Muscle) in myofibroblasts, Epcam in epithelial cells, and Pecam1 in endothelial cells, confirming robust cell-type annotation.</p>
<p>Comparative analysis of cellular composition between BLM and PBS (Phosphate-Buffered Saline) groups revealed noticeable shifts (<xref ref-type="fig" rid="F1">Figure 1d</xref>). BLM-treated lungs exhibited an increase in fibroblasts and myofibroblast-like cells, accompanied by a reduction in epithelial cells and endothelial cells, suggesting fibrotic remodeling and epithelial injury. Quantification of epithelial cell proportions (<xref ref-type="fig" rid="F1">Figure 1e</xref>) showed a marked decrease in the BLM group compared to PBS, though the difference did not reach statistical significance (ns, <italic>P</italic> &#x003E; 0.05).</p>
<p>These data demonstrate that bleomycin exposure induces pronounced cellular reorganization in the lung, with expansion of profibrotic mesenchymal populations and concomitant depletion of epithelial compartments, consistent with pathological hallmarks of IPF.</p>
<p>Next, we utilized GO (Gene Ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analyses were employed to investigate the functional roles of genes highly expressed in epithelial cells. The GO functions of 30 TOP genes screened by single-cell sequencing showed significant changes in the functions of positive regulation of EMT and response to mchanical stimulus (<xref ref-type="fig" rid="F2">Figure 2a</xref>). Meanwhile, based on functional annotations, it was found that the esrp1 was involved. The KEGG enrichment analysis demonstrated that epithelial cell&#x2013;associated genes were distributed across the RAP (Ras-related Protein), apelin, and sphingolipid signaling pathways (<xref ref-type="fig" rid="F2">Figure 2b</xref>). These results suggested that epithelial cells are critical population of EMT.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption><p>Differential gene expression and functional enrichment of lung epithelial cells in bleomycin-induced pulmonary fibrosis. <bold>(a)</bold> GO analysis of epithelial cell function. <bold>(b)</bold> KEGG pathway analysis of all cells. <bold>(c)</bold> To detect the expression and distribution of ESRP1 in each cell using Loupe software. <bold>(d)</bold> To detect the difference of ESRP1 in epithelial cells of lung tissue between two groups of mice. <bold>(e)</bold> Function and pathway analysis of ESRP1 gene with GO and KEGG.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmed-13-1734619-g002.tif">
<alt-text content-type="machine-generated">A collage of five panels presenting various data analyses: A. A bar graph showing Gene Ontology (GO) terms with color-coded bars indicating significance and categories such as biological processes and cellular components. B. A dot plot for KEGG enrichment analysis displaying top 20 pathways with dots varying in size and color according to p-value and number of genes. C. A violin plot labeled ESRP1 showing expression across different cell types, with epithelial cells exhibiting the highest expression. D. A violin plot comparing ESRP1 expression in PBS and BLM treated samples, indicating significant expression difference with annotations. E. A stacked bar graph illustrating significant biological processes, cellular components, molecular functions, and KEGG pathways categorized with color-coded p-values.</alt-text>
</graphic>
</fig>
<p>Subsequent genetic screening revealed specific expression of esrp1 in epithelial cells (<xref ref-type="fig" rid="F2">Figure 2c</xref>), and significant elevation in BLM-induced mice compared to control group (<xref ref-type="fig" rid="F2">Figure 2d</xref>). To further elucidate the function of ESRP1, GO and KEGG pathway analysis were conducted. The results showed that ESRP1 regulates RNA splicing and plays a key role in modulating the Rap1 signaling pathway and actin cytoskeleton, processes crucial for fibrosis progression (<xref ref-type="fig" rid="F2">Figure 2e</xref>).</p>
</sec>
<sec id="S2.SS2">
<label>2.2</label>
<title>ESRP1, Epac, and Rap1a are up-regulated in BLM-induced pulmonary fibrosis and IPF patients</title>
<p>To further clarify the expression of ESRP1, the current study analyzed the expression changes of ESRP1 in the public database GSE218997. The results showed that ESRP1 was highly expressed in BLM-induced lung tissue of mice (<xref ref-type="fig" rid="F3">Figure 3a</xref>). In addition, KEGG enrichment analysis indicated a significant association between the ESRP1 and Rap1a signaling pathways.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption><p>ESRP1 and Rap1a were both upregulated in the lung tissues of BLM-induced pulmonary fibrosis models. <bold>(a)</bold> GSE218997 data set search found that ESRP1 increased in BLM-induced lung tissue of mice. <bold>(b)</bold> In mouse lungs, ESRP1, Epac, and Rap1a levels were analyzed by western blot after 3 weeks of bleomycin or saline administration. <bold>(c)</bold> IHC was used to examine the levels of ESRP1, Epac, and Rap1a in the lung tissues of BLM-induced models (40 &#x00D7; ). <bold>(d)</bold> Multiplex immunofluorescence showing expression and co-localization of Epcam with ESRP1 or Rap1a in lung sections from indicated mouse groups (scale bar, 50 &#x03BC;m). Manders&#x2019; correlation coefficients quantify the degree of co-localization. Statistically significant differences are indicated as &#x002A;<italic>P</italic> &#x003C; 0.05, &#x002A;&#x002A;<italic>P</italic> &#x003C; 0.01, &#x002A;&#x002A;&#x002A;<italic>P</italic> &#x003C; 0.001, and &#x002A;&#x002A;&#x002A;&#x002A;<italic>P</italic> &#x003C; 0.0001.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmed-13-1734619-g003.tif">
<alt-text content-type="machine-generated">Multi-panel scientific image analyzing expression levels of ESRP1, Epac, and Rap1a. Panel (a) shows a volcano plot and a violin plot of expression differences between PBS and BLM treatments. Panel (b) includes Western blot images with associated bar graphs comparing protein and mRNA levels for ESRP1, Epac, and Rap1a between treatments. Panel (c) displays immunohistochemistry images of lung tissue sections stained for ESRP1, Epac, and Rap1a, with a bar graph quantifying relative IOD. Panel (d) contains immunofluorescence images showing Epcam/Rap1a/DAPI and Epcam/ESRP1/DAPI staining, with bar graphs of Manders&#x2019; Coefficients comparing PBS and BLM.</alt-text>
</graphic>
</fig>
<p>Small GTPases serve as multifunctional regulators involved in numerous cellular activities (<xref ref-type="bibr" rid="B29">29</xref>). As guanine nucleotide exchange factors (GEFs), Epac proteins mediate the activation of Rap small GTPases. Two isoforms are present in mammals: Epac1, expressed broadly across tissues, and Epac2 (RapGEF4 in humans), which shows tissue-restricted expression in the brain, kidney, and pancreas (<xref ref-type="bibr" rid="B30">30</xref>&#x2013;<xref ref-type="bibr" rid="B32">32</xref>). Rap1a activation can facilitate EMT by modulating the expression of cell adhesion molecules and orchestrating cytoskeletal reconfiguration, thereby influencing cell shape and movement (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>). Pathological activation of the Epac&#x2013;Rap1a axis in fibrotic tissues contributes to the amplification of EMT processes, subsequently enhancing extracellular matrix production and deposition, thereby aggravating the extent of fibrosis within lung tissue (<xref ref-type="bibr" rid="B35">35</xref>).</p>
<p>Hence, this study utilized western blot analysis together with qPCR to assess the expression patterns of the Epac&#x2013;Rap1a signaling axis. The results validated the increased expression of ESRP1, Epac, and Rap1a among mice exposed to BLM when evaluated against the control group (<xref ref-type="fig" rid="F3">Figure 3b</xref>). IHC was further conducted to confirm this result. As shown in <xref ref-type="fig" rid="F3">Figure 3c</xref>, the proteins which indicated by brown dots were located within alveolar and bronchial epithelial cells and exhibited higher expression levels in BLM group mice compared to the control group (<xref ref-type="fig" rid="F3">Figure 3c</xref>).</p>
<p>Furthermore, multiplex immunofluorescence revealed a progressive loss of the epithelial marker Epcam in BLM-exposed lungs compared with controls. Concomitantly, both ESRP1 and Rap1a signals were markedly elevated in fibrotic foci on day 21 (<xref ref-type="fig" rid="F3">Figure 3d</xref>). These results demonstrate that ESRP1 contributes to the development in BLM-treated mice, particularly through its impact on epithelial cells.</p>
<p>To validate the expression of ESRP1 in patients with pulmonary fibrosis, lung tissues from both normal and fibrotic samples were collected. H&#x0026;E staining revealed severe fibrosis in IPF patients compared to healthy controls, characterized by inflammatory cell infiltration and alveolar hemorrhage. Additionally, there was noticeable alveolar enlargement and thickening of the alveolar septa. Masson&#x2019;s trichrome staining indicated substantial collagen deposition, visible as intense blue staining around the bronchial walls and alveolar septum in IPF patients. Furthermore, IHC analysis demonstrated that protein levels of ESRP1, Epac, and Rap1a were elevated in IPF patients (<xref ref-type="fig" rid="F4">Figure 4a</xref>). IF analysis further corroborated the increased ESRP1 and Rap1a expression in IPF tissues, alongside a reduction in the epithelial cell marker Epcam (Epithelial Cell Adhesion Molecule). Additionally, no significant colocalization was observed between Epacm and ESRP1, or between Epcam and Rap1a (<xref ref-type="fig" rid="F4">Figure 4b</xref>). In healthy lung tissue, alveolar structures remained intact and exhibited only minimal ESRP1 expression, primarily localized to alveolar and bronchial cells. In contrast, lung tissue from IPF displayed disrupted alveolar architecture, proliferation of interstitial fibrous tissue, and elevated Esrp1 expression in bronchial epithelial cells as well as compressed alveolar surfaces. Collectively, these findings indicate that ESRP1 is specifically enriched in epithelial cells residing in the lungs of patients suffering from IPF.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption><p>ESRP1 and Rap1a were both upregulated in the lung tissues of IPF patients. <bold>(a)</bold> IPF was evaluated using H&#x0026;E staining, while collagen deposition through Masson&#x2019;s staining, and the levels of ESRP1, Epac, and Rap1a was detected immunohistochemically in healthy and IPF patients. <bold>(b)</bold> Multiplex immunofluorescence showing expression and co-localization of Epcam with ESRP1 or Rap1a in both HC and IPF groups (scale bar, 50 &#x03BC;m). Manders&#x2019; correlation coefficients quantify the degree of co-localization. Statistically significant differences are indicated as &#x002A;<italic>P</italic> &#x003C; 0.05, &#x002A;&#x002A;<italic>P</italic> &#x003C; 0.01, &#x002A;&#x002A;&#x002A;<italic>P</italic> &#x003C; 0.001, and &#x002A;&#x002A;&#x002A;&#x002A;<italic>P</italic> &#x003C; 0.0001.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmed-13-1734619-g004.tif">
<alt-text content-type="machine-generated">Panel (a) displays histological stainings of lung tissue from healthy controls (HC) and idiopathic pulmonary fibrosis (IPF) patients. The stains shown include H&#x0026;E, Masson&#x2019;s trichrome, ESRP1, Epac, and Rap1a. Panel (b) shows immunofluorescent images of lung tissues for Epcam/ESRP1/DAPI and Epcam/Rap1a/DAPI in HC and IPF, highlighting protein expression differences. The bottom graphs depict Manders&#x2019; coefficients for Epcam/Rap1a and Epcam/ESRP1, with significant differences indicated between HC and IPF groups, suggesting variations in protein interactions. Scale bars indicate 50 micrometers.</alt-text>
</graphic>
</fig>
</sec>
<sec id="S2.SS3">
<label>2.3</label>
<title>ESRP1 regulates Epac-Rap1a to promote EMT in MLE-12 cells</title>
<p><italic>In vitro</italic> studies, TGF-&#x03B2;1 serves as a central mediator initiating EMT. Therefore, protein expression analysis was conducted to evaluate EMT markers in 10 ng/mL TGF-&#x03B2;1 stimulated mouse lung epithelial cells (MLE-12). Western blot revealed that TGF-&#x03B2;1 markedly up-regulated ESRP1 protein and simultaneously triggered an EMT signature: E-cad was substantially down-regulated, whereas N-cad expression was significantly elevated (<xref ref-type="fig" rid="F5">Figure 5a</xref>). We also noted enhanced protein expression of Epac and Rap1a in TGF-&#x03B2;1-treated MLE-12 cells compared to the control group (<xref ref-type="fig" rid="F5">Figure 5a</xref>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption><p>ESRP1 regulates Rap1a to promote EMT in MLE-12 cells. <bold>(a)</bold> The protein expression levels of ESRP1, Epac, Rap1a, N-cad, and E-cad were measured in MLE-12 cells treated with 10 ng/ml TGF-&#x03B2;1 for 24 h. <bold>(b)</bold> IF analysis showed Rap1a (green signal) expression in both Control and TGF-&#x03B2;1-treated groups. <bold>(c)</bold> Co-IP demonstrating the interaction between ESRP1 and Epac in mouse MLE-12 lung epithelial cells. The protein detection results after IP were used for the quantitative analysis of protein-protein interactions. <bold>(d,e)</bold> Following 48 h of lentiviral exposure, MLE-12 cells were subjected to TGF-&#x03B2;1 stimulation for 24 h, siRNA, lentivirus, siRNA+ TGF-&#x03B2;1 and lentivirus + TGF-&#x03B2;1, the levels of ESRP1, N-cad, and E-cad were determined by qPCR and Western Blot. Quantified by densitometric analysis. The data is expressed as average &#x00B1; SD. Statistically significant differences are indicated as &#x002A;<italic>P</italic> &#x003C; 0.05, &#x002A;&#x002A;<italic>P</italic> &#x003C; 0.01, &#x002A;&#x002A;&#x002A;<italic>P</italic> &#x003C; 0.001, and &#x002A;&#x002A;&#x002A;&#x002A;<italic>P</italic> &#x003C; 0.0001.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmed-13-1734619-g005.tif">
<alt-text content-type="machine-generated">A series of panels illustrating the effects of TGF-&#x03B2;1 on protein and mRNA expression. Panel (a) shows Western blots and bar graphs comparing ESRP1, Epac, Rap1a, N-cad, and E-cad levels between CON and TGF-&#x03B2;1 conditions. Panel (b) contains fluorescence microscopy images of Rap1a expression with corresponding quantification. Panel (c) displays an immunoprecipitation assay for ESRP1 and Epac, with bar graph quantification. Panel (d) presents Western blots and bar graphs showing effects of sh-Esrp1 and oe-Esrp1 on ESRP1, N-cad, and E-cad expression under TGF-&#x03B2;1 treatment. Panel (e) features bar graphs of mRNA expression for esrp1, n-cad, and e-cad under various conditions. Statistical significance is indicated by asterisks.</alt-text>
</graphic>
</fig>
<p>Cellular IF (Immunofluorescence) assays further confirmed TGF-&#x03B2;1 treatment increased the expression of Rap1a in the cytoplasm (<xref ref-type="fig" rid="F5">Figure 5b</xref>). KEGG pathway enrichment predicted a potential association between ESRP1 and the Rap1 signaling cascade. To assess the interaction between ESRP1 and Epac, Co-IP was performed on lysates from MLE-12 cells treated with or without TGF-&#x03B2;1. The results showed that anti-ESRP1 antibody co-precipitated Epac from cell lysates. In contrast, normal IgG control antibody failed to precipitate either protein, confirming the specificity of the interaction. Quantitative analyses revealed that TGF-&#x03B2;1 treatment enhanced the interaction between ESRP1 and Epac (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>) (mean &#x00B1; SEM, <italic>n</italic> = 3, &#x002A;&#x002A;&#x002A;<italic>P</italic> &#x003C; 0.001; <xref ref-type="fig" rid="F5">Figure 5c</xref>). Thus, TGF-&#x03B2;1 stimulation significantly enhanced the Co-IP enrichment of both Epac and ESRP1, indicating a ligand-induced increase in their mutual association. Moreover, TGF-&#x03B2;1 treatment markedly enhanced this interaction, as quantified by densitometric analysis of precipitated proteins.</p>
<p>Furthermore, MLE-12 cells were transduced with lentiviral vectors to silence or overexpress <italic>esrp1</italic>, and its expression were quantified by Western Blot and qPCR. <italic>Esrp1</italic> knockdown markedly reduced the expression of N-cad, whereas E-cad was significantly increased. Conversely, <italic>esrp1</italic> overexpression elevated N-cad transcripts and concurrently suppressed E-cad (<xref ref-type="fig" rid="F5">Figures 5d,e</xref>). These reciprocal changes indicate that ESRP1 transcriptionally regulates EMT.</p>
<p>To elucidate ESRP1 function, lentivirus-mediated gene perturbation was performed in MLE-12 cells. Compared with scrambled controls, <italic>esrp1</italic> silencing markedly attenuated the expression of Epac, Rap1a and N-cad, while reciprocally enhancing E-cad abundance. Conversely, overexpression <italic>esrp1</italic> elevated Epac, Rap1a and N-cad, accompanied by a concomitant reduction in E-cad (<xref ref-type="fig" rid="F6">Figure 6a</xref>). Collectively, these data demonstrate that ESRP1 positively modulates Epac and Rap1a expression and actively drives EMT.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption><p>ESRP1 promote EMT via Epac-Rap1a in MLE-12 cells. <bold>(a)</bold> Lentiviral <italic>esrp1</italic> knockdown or overexpression induces parallel changes in Epac and Rap1a. <bold>(b)</bold> siRNA-mediated <italic>epac</italic> silencing does not alter ESRP1 but decreases N-cad and increases E-cad. <bold>(c)</bold> siRNA-mediated <italic>rap1a</italic> silencing leaves Epac and ESRP1 unchanged while similarly reducing N-cad and elevating E-cad. Bar graphs show mean &#x00B1; SEM; &#x002A;<italic>P</italic> &#x003C; 0.05, &#x002A;&#x002A;<italic>P</italic> &#x003C; 0.01. &#x002A;&#x002A;&#x002A;<italic>P</italic> &#x003C; 0.001. &#x002A;&#x002A;&#x002A;&#x002A;<italic>P</italic> &#x003C; 0.0001. <bold>(d)</bold> Representative Western blot and quantitative analysis of Rap1a, Epac, ESRP1, E-cad, and N-cad in cells treated with TGF-&#x03B2;1 or without <italic>esrp1</italic> overexpression and/or <italic>epac</italic> silencing.</p></caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fmed-13-1734619-g006.tif">
<alt-text content-type="machine-generated">Western blot and bar graph data showing protein expression under different conditions for panels a, b, c, and d. Each panel details the effects of various treatments such as sh-Esrp1, oe-Esrp1, TGF-&#x03B2;1, si-Epac, and si-Rap1a on proteins like Epac, Rap1a, ESRP1, N-cad, and E-cad. The bar graphs compare relative protein expression levels with statistical significance indicated by asterisks.</alt-text>
</graphic>
</fig>
<p>To clarify the regulatory hierarchy among ESRP1, Epac, and Rap1a, MLE-12 cells were transfected with siRNAs targeting <italic>epac</italic> and <italic>rap1a</italic>. Knockdown of <italic>epac</italic> markedly reduced Rap1a and N-cad levels while increasing E-cad (<xref ref-type="fig" rid="F6">Figure 6b</xref>); conversely, silencing <italic>rap1a</italic> decreased N-cad and elevated E-cad without affecting Epac abundance (<xref ref-type="fig" rid="F6">Figure 6c</xref>). These results corroborate that the Epac&#x2013;Rap1a axis promotes EMT. Critically, neither Epac nor Rap1a depletion altered ESRP1 expression, whereas <italic>epac</italic> knockdown Rap1a expression. Collectively, the data establish that ESRP1 operates upstream of Epac and Rap1a, with Epac positioned upstream of Rap1a in this signaling cascade. These findings indicated that ESRP1 facilitated TGF-&#x03B2;1-induced EMT by activating Epac-Rap1a signaling <italic>in vitro</italic>.</p>
<p>Upon TGF-&#x03B2;1 stimulation, the protein levels of Rap1a, Epac, ESRP1, and N-cadherin were markedly increased compared with the CON group, whereas E-cadherin was progressively reduced. Notably, ESRP1 overexpression further amplified the TGF-&#x03B2;1&#x2013;induced changes, as evidenced by higher Rap1a/Epac/ESRP1/N-cadherin expression and a more pronounced decrease in E-cadherin in the oe-Esrp1 + TGF-&#x03B2;1 group. In contrast, in the si-Epac + TGF-&#x03B2;1 group, Rap1a, Epac, ESRP1, and N-cadherin levels were reduced and E-cadherin was elevated relative to the oe-Esrp1 + TGF-&#x03B2;1 group. Importantly, no significant differences were observed in EMT-associated markers or the target proteins between si-Epac + TGF-&#x03B2;1 and si-Epac + oe-Esrp1 + TGF-&#x03B2;1 groups, indicating that Epac knockdown prevented ESRP1 overexpression induce EMT marker alterations under TGF-&#x03B2;1 stimulation (<xref ref-type="fig" rid="F6">Figure 6d</xref>).</p>
</sec>
</sec>
<sec id="S3" sec-type="discussion">
<label>3</label>
<title>Discussion</title>
<p>Integrated analyses of clinical IPF samples, mouse, cell models, and functional interventions reveal a critical role for the ESRP1-Epac-Rap1a signaling axis in driving EMT in alveolar epithelial cells during IPF. Our results showed that ESRP1 is specifically high expressed in IPF lung tissue and TGF-&#x03B2;<sub>1</sub>-stimulated MLE-12 cells, correlating positively with fibrotic severity. Gain- and loss-of-function experiments demonstrate that ESRP1 directly promotes the expression of Epac and Rap1a, consequently upregulating N-cad and downregulating E-cad. It is worth noting that interference with Epac or Rap1a does not affect ESRP1 expression, positioning ESRP1 upstream within this signaling cascade.</p>
<p>While ESRP1 is a well-established RNA splicing regulator that typically maintains epithelial integrity and suppresses EMT in cancer, our findings reveal its paradoxical pro-fibrotic role in IPF. Within the IPF microenvironment, TGF-&#x03B2;<sub>1</sub> induces aberrant ESRP1 overexpression, which disrupts epithelial homeostasis to promote fibrosis. We propose that chronic inflammatory signals in fibrotic diseases subvert ESRP1&#x2019;s physiological function, converting it to a pro-fibrotic effector. Mechanistically, we identify a novel TGF-&#x03B2;<sub>1</sub>/ESRP1- Epac-Rap1a axis driving EMT in IPF. KEGG and experimental validation demonstrate ESRP1&#x2019;s transcriptional/post-transcriptional control of Rap1a signaling through this axis. Crucially, Epac/Rap1a knockdown phenocopied ESRP1 loss-induced EMT inhibition without altering ESRP1 levels, confirming their essential downstream effector roles. This aligns with conserved profibrotic Rap1a mechanisms (<xref ref-type="bibr" rid="B35">35</xref>), suggesting cross-fibrotic disease relevance.</p>
<p>ESRP1 warrants evaluation as a novel biomarker for IPF diagnosis and disease activity monitoring. Furthermore, targeting ESRP1 or its downstream effectors Epac and Rap1a presents a promising therapeutic strategy to inhibit pathogenic EMT while potentially preserving basal epithelial function, offering greater specificity than broad-spectrum antifibrotics. Existing Epac inhibitors (<xref ref-type="bibr" rid="B21">21</xref>), primarily explored in oncology, could be repurposed for fibrotic diseases based on this mechanistic foundation.</p>
<p>While several studies indicate that ESRP1&#x2019;s downregulation is associated with tumor progression and EMT, our findings suggest that ESRP1 overexpression in lung epithelial cells contributes to fibrosis. Pathway analysis using KEGG highlighted the pivotal role of ESRP1 in modulating Rap1a signaling and actin cytoskeletal remodeling. The reduction in epithelial cells observed in this study may be due to increased ESRP1 expression, which promotes their transition to fibroblasts via the Epac-Rap1a pathway. We further investigated whether the impact of ESRP1 on EMT is mediated through the Epac-Rap1a pathway. Our results demonstrated that Epac knockdown effectively neutralized the regulatory influence of ESRP1 on TGF-&#x03B2;1 induced EMT markers. Even with the upregulation of ESRP1, cells with depleted Epac remained unresponsive in terms of EMT marker expression, suggesting that ESRP1-mediated EMT regulation is Epac-dependent. This identifies the ESRP1-Epac-Rap1a axis as a critical molecular link in controlling cellular identity and mesenchymal transformation.</p>
<p>In spite of the strength of the evidence presented, several limitations of the current work should be recognized. First, the absence of human-derived epithelial cells in our <italic>in vitro</italic> experiments restricts the direct applicability of these findings to clinical settings. The heterogeneity in human IPF and potential differences in EMT pathways across species suggest that further studies using human lung tissue or primary epithelial cells from IPF patients would provide a more accurate picture of ESRP1&#x2019;s role in EMT. Furthermore, although we identified Epac-Rap1a as a downstream signaling pathway of ESRP1, other pathways may also contribute to EMT in IPF and should be explored in future research.</p>
<p>Our study underscores the role of Esrp1 in promoting EMT and fibrosis via Epac-Rap1a signaling, reinforcing the importance of EMT in IPF progression. Our findings propose ESRP1 as a potential therapeutic target, although further research is required to elucidate its mechanism and evaluate its clinical relevance in human patients. By addressing these limitations and further investigating ESRP1&#x2019;s multifaceted role, future research may yield novel insights and therapeutic avenues for combating IPF.</p>
</sec>
<sec id="S4" sec-type="conclusion">
<label>4</label>
<title>Conclusion</title>
<p>In summary, our study demonstrated that ESRP1 is significantly upregulated in alveolar epithelial cells during the progression of IPF. Furthermore, ESRP1 facilitated EMT by activating Epac-Rap1a axis, ultimately leading to the advancement of IPF. By demonstrating the role of ESRP1 in EMT, this study provides a theoretical foundation for exploiting ESRP1 as a therapeutic target in the design of new treatment strategies for pulmonary fibrosis.</p>
</sec>
<sec id="S5" sec-type="materials|methods">
<label>5</label>
<title>Materials and methods</title>
<sec id="S5.SS1">
<label>5.1</label>
<title>Lung tissue collection</title>
<p>Written informed consent was secured from every participant prior to enrollment, and the study protocol was reviewed and approved by the Institutional Review Board at the General Hospital of Ningxia Medical University (Approval No. KYLL-2023-0516) and conducted in accordance with NIH guidelines. Patients diagnosed with lung cancer and lung fibrosis, as identified by CT scans, were recruited from Ningxia, Yinchuan. Samples were collected from areas &#x2265; 5 cm away from the tumor as healthy controls. The tissue collection occurred between January 2024 and October 2024. IPF diagnosis was based on clinical history, physical exams, pulmonary function tests, HRCT (High-Resolution Computed Tomography), and confirmed by lung biopsy, in alignment with the recommendations issued jointly by the American Thoracic Society (ATS) and the European Respiratory Society (ERS) (<xref ref-type="bibr" rid="B3">3</xref>). Healthy Control (HC) samples were obtained from lung cancer patients with histologically normal lung tissue. Additionally, lungs from healthy organ donors and IPF transplant donors were used. All tissue usage was approved by the relevant institutional review boards.</p>
</sec>
<sec id="S5.SS2">
<label>5.2</label>
<title>Reagents and antibodies</title>
<p>Unless otherwise specified, all reagents were purchased from sigma-Aldrich. BLM was sourced from Solarbio (Cat:IB0871; Beijing, China) for use in the experiments, while recombinant cytokine TGF-&#x03B2;1 was supplied by R&#x0026;D Systems (Hong Kong, China). The primary antibody against ESRP1 (rabbit polyclonal, Cat No. 21045-1-AP), Epac (rabbit polyclonal, Cat No. 12572-1-AP), Rap1a (mouse monoclonal, Cat No. 68125-1-Ig), N-cadherin (rabbit polyclonal, Cat No. 22018-1-AP) and &#x03B2;-actin (rabbit polyclonal, Cat No. 20536-1-AP) were obtained from Proteintech (Wuhan, China). E-cadherin (rabbit polyclonal, Cat No.#AF0131) was purchased from Affinity (Jiangsu, China). Multiplex immunofluorescence staining was performed according to the manufacturer&#x2019;s instructions using the Servicebio multiplex immunofluorescence kit (Servicebio, Wuhan, China). The istological and immunohistochemical reagents used in this study were obtained from Zhong-shan-Jin-qiao Biotechnology (Beijing, China). Quantitative real-time PCR kits were sourced from Vazyme (Nanjing, China), and siRNA along with other chemical reagents from Sangon Biotech (Shanghai, China).</p>
</sec>
<sec id="S5.SS3">
<label>5.3</label>
<title>The construction of BLM-induced mouse IPF model</title>
<p>The conduct of animal experiments followed the directives and approval of the Ethics Committee for Animal Research (Approval Number: IACUC-NYLAC-2023-252). Male C57BL/6J mice (22 &#x00B1; 2 g, aged 6&#x2013;8 weeks) were acquired from the Animal Centre of Ningxia Medical University and used to establish the IPF model. The mice were maintained in a specific pathogen-free (SPF) facility, where they had continuous access to potable water and a nutritionally balanced standard chow diet provided <italic>ad libitum</italic>. After intraperitoneal anesthesia with 0.1 % pentobarbital sodium (50 mg kg<sup>&#x2212;1</sup>), IPF was established through a single intratracheal administration of bleomycin sulfate at a dose of 2 mg/kg dissolved in 50 &#x03BC;L of sterile 0.9% saline. Control mice received an equal volume of vehicle alone. Animals were monitored daily for body weight and general condition. On day 21 post-instillation, mice were euthanized by exsanguination under deep anesthesia, after which lungs were harvested for histopathological examination and biochemical analyses.</p>
</sec>
<sec id="S5.SS4">
<label>5.4</label>
<title>Sequencing with 10 &#x00D7; Genomics platform</title>
<p>Lung tissues from mice in the PBS and BLM groups were dissociated into single-cell suspensions and loaded onto a Chromium Single Cell Controller (10 &#x00D7; Genomics, United States) for single-cell library construction and sequencing. Raw base call files were processed with Cell Ranger (v6.0) to perform demultiplexing, alignment, and UMI counting, and reads were mapped to the mouse reference genome (mm10) to generate the gene&#x2013;cell count matrix. Downstream analyses were conducted in R using the Seurat workflow. Cells were retained after quality control based on standard metrics (including the number of detected genes/UMIs and the proportion of mitochondrial transcripts), and low-quality cells were removed. The filtered data were normalized and scaled, highly variable genes were identified, and principal component analysis (PCA) was performed. Graph-based clustering was conducted using a shared nearest neighbor (SNN) graph built on the top 10 principal components, and visualization was generated with Uniform Manifold Approximation and Projection (UMAP; RunUMAP). Differentially expressed genes (DEGs) for each cluster (or between groups when applicable) were identified using a Wilcoxon rank-sum test, and multiple testing correction was applied to control the false discovery rate (FDR). Functional enrichment analyses were performed for GO terms and KEGG pathways using curated databases, and significantly enriched terms/pathways were defined based on adjusted <italic>P</italic>-values.</p>
</sec>
<sec id="S5.SS5">
<label>5.5</label>
<title>Cell culture and the construction of EMT cell model</title>
<p>According to the manufacturer&#x2019;s guidelines, the MLE-12 were acquired from the Shanghai iCell Bioscience Institute (iCell-m036) and cultured in DMEM/F12 basal medium with added supplements (iCell-0033a). Cells were maintained in a humidified incubator under sterile conditions at 37&#x00B0;C with 5% CO2 until reaching 80&#x2013;90% confluence. After seeding in 6-well plates overnight, the cells were stimulated with TGF-&#x03B2;<sub>1</sub> (10 ng/mL) for 24 h to construct EMT cell model and then collected for qPCR and western blot.</p>
</sec>
<sec id="S5.SS6">
<label>5.6</label>
<title>Lentiviral transduction and siRNA transfection</title>
<p>MLE-12 cells were plated into 6-well plates then infected with the designated lentiviral constructs plus 2 &#x03BC;g/ml polybrene at 70% confluence overnight, followed by 2 &#x03BC;g/mL puromycin selection for 3 days. siRNA duplexes targeting gene-<italic>epac/rap1a</italic> were transfected at 50 nM using Lipofectamine RNAiMAX according to the manufacturer&#x2019;s instructions. After 48 h, qPCR and western blot assays were employed to verify knockdown efficiency. The sequence of siRNA used in present study was attached to <xref ref-type="table" rid="T2">Table 2</xref>. The sequences of the siRNAs (<italic>epac</italic> and <italic>raap1a</italic>) used in the present study are listed in <xref ref-type="table" rid="T3">Table 3</xref>.</p>
<table-wrap position="float" id="T2">
<label>TABLE 2</label>
<caption><p>Primers used in this study (Sangon Biotech).</p></caption>
<table cellspacing="5" cellpadding="5" frame="box" rules="all">
<thead>
<tr>
<th valign="top" align="left">Gene name</th>
<th valign="top" align="left">Gene ID</th>
<th valign="top" align="left">Forward primer (5&#x2019;&#x2013;3&#x2019;)</th>
<th valign="top" align="left">Reverse primer (5&#x2019;&#x2013;3&#x2019;)</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">Esrp1</td>
<td valign="top" align="left">207,920</td>
<td valign="top" align="left">CAAGCTGGGTTCGGATGAGAA</td>
<td valign="top" align="left">AGGTTTTCGGCGTCTATTTTAGT</td>
</tr>
<tr>
<td valign="top" align="left">N-cadherin</td>
<td valign="top" align="left">12,558</td>
<td valign="top" align="left">AGCGCAGTCTTACCGAAGG</td>
<td valign="top" align="left">TCGCTGCTTTCATACTGAACTTT</td>
</tr>
<tr>
<td valign="top" align="left">Fibronectin</td>
<td valign="top" align="left">14,268</td>
<td valign="top" align="left">ATGTGGACCCCTCCTG<break/> ATAGT</td>
<td valign="top" align="left">GCCCAGTGATTTCAGCAAAGG</td>
</tr>
<tr>
<td valign="top" align="left">Vimentin</td>
<td valign="top" align="left">22,352</td>
<td valign="top" align="left">TCCACACGCACCTACA<break/> GTCT</td>
<td valign="top" align="left">CCGAGGACCGGGTCACATA</td>
</tr>
<tr>
<td valign="top" align="left">&#x03B1;-SMA</td>
<td valign="top" align="left">11475</td>
<td valign="top" align="left">GTCCCAGACATCAGGG<break/> AGTAA</td>
<td valign="top" align="left">TCGGATACTTCAGCGTCAGGA</td>
</tr>
<tr>
<td valign="top" align="left">Zeb1</td>
<td valign="top" align="left">21,417</td>
<td valign="top" align="left">GCTGGCAAGACAACGT<break/> GAAAG</td>
<td valign="top" align="left">GCCTCAGGATAAATGACGGC</td>
</tr>
<tr>
<td valign="top" align="left">Epac</td>
<td valign="top" align="left">223,864</td>
<td valign="top" align="left">GCACGCTGCTCAATATGGTG</td>
<td valign="top" align="left">CGGTGCTCGAACACTAGCTG</td>
</tr>
<tr>
<td valign="top" align="left">Rap1a</td>
<td valign="top" align="left">109,905</td>
<td valign="top" align="left">ATGCGTGAGTACAAGCTAGTAGT</td>
<td valign="top" align="left">AATCTACCTCGACTTGCTTTCTG</td>
</tr>
<tr>
<td valign="top" align="left">&#x03B2;-actin</td>
<td valign="top" align="left">11,461</td>
<td valign="top" align="left">CATGTACGTTGCTATCCAGGC</td>
<td valign="top" align="left">CTCCTTAATGTCACGCACGAT</td>
</tr>
<tr>
<td valign="top" align="left">Rap1a</td>
<td valign="top" align="left">109,905</td>
<td valign="top" align="left">ATGCGTGAGTACAAGCTAGTAGT</td>
<td valign="top" align="left">AATCTACCTCGACTTGCTTTCTG</td>
</tr>
<tr>
<td valign="top" align="left">Epac</td>
<td valign="top" align="left">223,864</td>
<td valign="top" align="left">GCACGCTGCTCAATATGGTG</td>
<td valign="top" align="left">CGGTGCTCGAACACTAGCTG</td>
</tr>
</tbody>
</table></table-wrap>
<table-wrap position="float" id="T3">
<label>TABLE 3</label>
<caption><p>siRNA sequence used in this study (Sangon Biotech).</p></caption>
<table cellspacing="5" cellpadding="5" frame="box" rules="all">
<thead>
<tr>
<th valign="top" align="left">Gene name</th>
<th valign="top" align="left">Sense</th>
<th valign="top" align="left">AntiSense</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left"><italic>epac</italic></td>
<td valign="top" align="left">GCUGGACACCACUUACCAA/<break/>dT//dT/</td>
<td valign="top" align="left">UUGGUAAGUGGUGUCCAGC/<break/>dT//dT/</td>
</tr>
<tr>
<td valign="top" align="left"><italic>rap1a</italic></td>
<td valign="top" align="left">CAGCAAUGAGGGAUUUGUA/<break/>dT//dT/</td>
<td valign="top" align="left">UACAAAUCCCUCAUUGCUG/<break/>dT//dT/</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p><italic>FGFR2-IIIb</italic> and <italic>FGFR2-IIIc</italic>, alternative splicing isoforms of Fibroblast Growth Factor Receptor 2.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="S5.SS7">
<label>5.7</label>
<title>Histopathology</title>
<p>Left lungs were fixed overnight in 4% paraformaldehyde, embedded in paraffin, and cut into 4 &#x03BC;m sections. After deparaffinization and rehydration, the slides were stained with hematoxylin and eosin (H&#x0026;E) to examine tissue architecture and with Masson&#x2019;s trichrome to evaluate collagen distribution, following the manufacturer&#x2019;s recommendations. Additional sections were subjected to immunohistochemical analysis.</p>
</sec>
<sec id="S5.SS8">
<label>5.8</label>
<title>Immunohistochemistry (IHC) analysis</title>
<p>Cells were first dewaxing and rehydration, followed by antigen retrieval. Endogenous peroxidase activity was removed and incubated with 5% BSA. 1 h later, the sections were stained overnight at 4&#x00B0;C with rabbit anti-Fn (Abcam; Cat: ab2413; Dilution: 1:400), rabbit anti-Vim (Abcam; Cat: ab92547; Dilution: 1:600), rabbit anti-&#x03B1;-SMA (CST; Cat:19245S; Dilution: 1:200), and rabbit anti-ESRP1 (Proteintech;Cat No. 21045-1-AP; Dilution: 1:100), Epac (Proteintech; Cat No. 12572-1-AP; Dilution: 1:200), Rap1a (Proteintech; Cat No. 68125-1-Ig; Dilution: 1:50) and subsequently incubated with the streptavidin-biotin complex (ABC) detection kit (BOSTER, China) for 30 min at room temperature. Each section underwent color development using peroxidase-linked avidin/biotin and 3&#x2019;-3-diaminobenzidine (DAB) substrate from ZSGB-BIO, Cat# PV-6000D, followed by haematoxylin counterstaining.</p>
</sec>
<sec id="S5.SS9">
<label>5.9</label>
<title>Immunofluorescence analysis</title>
<p>Paraffin-embedded sections were dewaxed, rehydrated, and subjected to antigen retrieval using 10 mM sodium citrate buffer (pH 6.0) at 95&#x00B0;C for 15 min. Endogenous peroxidase activity was neutralized with 3% hydrogen peroxide for 10 min, and nonspecific binding was blocked with 5% normal donkey serum for 1 h at room temperature. Slides were then incubated overnight at 4&#x00B0;C with the respective primary antibodies (ESRP1 1:200; Rap1a 1:200) in a humidified chamber. After three 5-min PBS washes, slides were treated with HRP-conjugated secondary antibody for 1 h and developed with iF488-TSA (10 min, RT, dark). A second round of heat-mediated antigen retrieval was performed, followed by incubation with anti-EpCAM (1:100) and the corresponding secondary antibody and iF555-TSA using the same washing regime. Nuclei were counterstained with DAPI (4&#x2019;,6-Diamidino-2-Phenylindole, Dihydrochloride) for 10 min, autofluorescence quenched for 5 min and sections rinsed under running water for 10 min. Slides were mounted in Prolong Diamond and imaged with a Leica DMi8 confocal microscope.</p>
</sec>
<sec id="S5.SS10">
<label>5.10</label>
<title>Hydroxyproline assay</title>
<p>The concentration of hydroxyproline in the lungs was measured with a commercial ELISA (Enzyme-Linked Immunosorbent Assay) kit (A030-2-1) from Nanjing Jiancheng Bioengineering Institute, following the manufacturer&#x2019;s guidelines.</p>
</sec>
<sec id="S5.SS11">
<label>5.11</label>
<title>Western blotting analysis</title>
<p>Whole proteins were isolated using the Whole Cell Lysis Assay kit (KeyGEN5303, Nanjing, China). Cytoplasmic and nuclear proteins were isolated using the Nuclear and Cytoplasmic Protein Extraction Kit (KGB5302, Nanjing, China) according to the manufacturer&#x2019;s instructions. Cells were collected and incubated with a cytoplasmic extraction buffer on ice, followed by centrifugation to obtain the cytoplasmic supernatant. The remaining pellets were then resuspended in a nuclear extraction buffer to recover nuclear proteins. Histone-3 and &#x03B2;-actin were employed as internal controls for the nuclear and cytoplasmic fractions, respectively. Equal protein quantities from each sample were separated on a 10% gel, transferred to PVDF membranes, and probed with primary antibodies at 4&#x00B0;C overnight followed by appropriate secondary antibodies (Proteintech, SA00001-2). The protein bands were identified and measured using Superstar ECL (KeyGEN, Nanjing, China) with the Gel Imaging System (Amersham Imagequant800uv, United States). The results were quantitative analysis by using Image J. The antibodies utilized in this research include: rabbit anti-N-cad (1:1,000), rabbit anti-E-cad (1:1,000), mouse anti-Rap1a (1:1,000), rabbit anti-Epac (1:500), and rabbit anti-Esrp1 (1:1,000) and anti-&#x03B2;-actin (1:2,500) polyclonal antibodies were purchased from Proteintech (Wuhan, Hubei, China). The relative expression of target proteins was determined by comparing the gray level ratio of the target bands to &#x03B2;-actin, which served as an internal control.</p>
</sec>
<sec id="S5.SS12">
<label>5.12</label>
<title>Quantitative PCR</title>
<p>RNA extraction was carried out with TRIzol reagent (Ambion, United States). A total of 1 &#x03BC;g RNA was then subjected to reverse transcription using a cDNA synthesis kit, following the manufacturer&#x2019;s instructions (Vazyme Biotech, Nanjing, China). quantitative PCR was performed on a Bio-Rad IQ5 system (Bio-Rad Inc., United States) using HiScript Q RT SuperMix for qPCR (Vazyme, Nanjing, China). Expression levels were normalized against &#x03B2;-actin as the housekeeping gene, and fold changes were computed by applying the 2<sup>&#x2013;&#x25B3;&#x25B3;CT</sup> algorithm. Details of the primer sequences designed for the amplification of mouse genes are presented in <xref ref-type="sec" rid="S13">Supplementary Table 1</xref>.</p>
</sec>
<sec id="S5.SS13">
<label>5.13</label>
<title>Co-immunoprecipitation</title>
<p>Cells at 80% confluence were washed twice with chilled PBS and lysed for 30 min on ice using RIPA buffer supplemented with protease inhibitors. Lysates were centrifuged at 12,000 rpm for 15 min at 4&#x00B0;C, and the supernatant was designated as the total protein extract. A minor aliquot of the lysate was retained as the input control. Co-IP was performed with the Beyotime Co-IP kit (P2179S) according to the manufacturer&#x2019;s instructions.</p>
<p>Briefly, the total protein extract was incubated with primary antibodies against ESRP1 (rabbit polyclonal, ProteinTech, Cat No. 21045-1-AP) or Epac (rabbit polyclonal, ProteinTech, Cat No. 12572-1-AP) at 4&#x00B0;C overnight with gentle rotation. For the negative control, an equal amount of normal rabbit IgG (ProteinTech, Cat No. B900610) was used instead of the specific primary antibody. Subsequently, protein A/G agarose beads (included in the Beyotime Co-IP kit) were added to the mixture and incubated for another 4 h at 4&#x00B0;C. After incubation, the beads were washed five times with ice-cold IP wash buffer (provided in the kit) to remove non-specific bindings, and the immunoprecipitated complexes were eluted with elution buffer (included in the kit) by boiling at 95&#x00B0;C for 10 min. The eluted samples, along with the input control, were subjected to Western blot analysis as described below.</p>
</sec>
<sec id="S5.SS14">
<label>5.14</label>
<title>Statistical analysis</title>
<p>All data in this study were derived from a minimum of three independent experiments for each condition. Statistical analysis was performed using GraphPad Prism 9.5 (GraphPad Software Inc., United States). Statistical analyses included one-way ANOVA for comparisons among multiple groups with a common control and Student&#x2019;s <italic>t</italic>-tests for pairwise analyses. Data are expressed as mean &#x00B1; SD. A probability value of &#x003C; 0.05 was regarded as statistically significant, with symbols denoting significance as follows: &#x002A;<italic>P</italic> &#x003C; 0.05, &#x002A;&#x002A;<italic>P</italic> &#x003C; 0.01, &#x002A;&#x002A;&#x002A;<italic>P</italic> &#x003C; 0.001, and &#x002A;&#x002A;&#x002A;&#x002A;<italic>P</italic> &#x003C; 0.0001.</p>
</sec>
</sec>
</body>
<back>
<sec id="S6" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in this study are included in this article/Supplementary Material, further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="S7" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>The studies involving humans were approved by Institutional Review Board at the General Hospital of Ningxia Medical University (Approval No. KYLL-2023-0516). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. The animal study was approved by Ethics Committee for Animal Research (Approval Number: IACUC-NYLAC-2023-252). The study was conducted in accordance with the local legislation and institutional requirements. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p>
</sec>
<sec id="S8" sec-type="author-contributions">
<title>Author contributions</title>
<p>RQ: Writing &#x2013; original draft, Investigation, Methodology, Data curation. JW: Methodology, Writing &#x2013; original draft. GC: Methodology, Writing &#x2013; original draft. TZ: Formal analysis, Writing &#x2013; original draft. ZH: Formal analysis, Writing &#x2013; original draft. JY: Writing &#x2013; review &#x0026; editing. YJ: Writing &#x2013; review &#x0026; editing. JC: Funding acquisition, Writing &#x2013; review &#x0026; editing, Resources, Supervision.</p>
</sec>
<sec id="S10" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="S11" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec id="S12" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="S13" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmed.2026.1734619/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fmed.2026.1734619/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Image_1.tif" id="FS1" mimetype="image/tiff"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kliment</surname> <given-names>CR</given-names></name> <name><surname>Englert</surname> <given-names>JM</given-names></name> <name><surname>Gochuico</surname> <given-names>BR</given-names></name> <name><surname>Yu</surname> <given-names>G</given-names></name> <name><surname>Kaminski</surname> <given-names>N</given-names></name> <name><surname>Rosas</surname> <given-names>I</given-names></name><etal/></person-group> <article-title>Oxidative stress alters syndecan-1 distribution in lungs with pulmonary fibrosis.</article-title> <source><italic>J Biol Chem.</italic></source> (<year>2009</year>) <volume>284</volume>:<fpage>3537</fpage>&#x2013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M807001200</pub-id> <pub-id pub-id-type="pmid">19073610</pub-id></mixed-citation></ref>
<ref id="B2">
<label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richeldi</surname> <given-names>L</given-names></name> <name><surname>Collard</surname> <given-names>HR</given-names></name> <name><surname>Jones</surname> <given-names>MG</given-names></name></person-group>. <article-title>Idiopathic pulmonary fibrosis.</article-title> <source><italic>Lancet.</italic></source> (<year>2017</year>) <volume>389</volume>:<fpage>1941</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(17)30866-8</pub-id> <pub-id pub-id-type="pmid">28365056</pub-id></mixed-citation></ref>
<ref id="B3">
<label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raghu</surname> <given-names>G</given-names></name> <name><surname>Collard</surname> <given-names>HR</given-names></name> <name><surname>Egan</surname> <given-names>JJ</given-names></name> <name><surname>Martinez</surname> <given-names>FJ</given-names></name> <name><surname>Behr</surname> <given-names>J</given-names></name> <name><surname>Brown</surname> <given-names>KK</given-names></name><etal/></person-group> <article-title>An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.</article-title> <source><italic>Am J Respir Crit Care Med.</italic></source> (<year>2011</year>) <volume>183</volume>:<fpage>788</fpage>&#x2013;<lpage>824</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.2009-040GL</pub-id> <pub-id pub-id-type="pmid">21471066</pub-id></mixed-citation></ref>
<ref id="B4">
<label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spagnolo</surname> <given-names>P</given-names></name> <name><surname>Maher</surname> <given-names>TM</given-names></name> <name><surname>Richeldi</surname> <given-names>L</given-names></name></person-group>. <article-title>Idiopathic pulmonary fibrosis: recent advances on pharmacological therapy.</article-title> <source><italic>Pharmacol Ther.</italic></source> (<year>2015</year>) <volume>152</volume>:<fpage>18</fpage>&#x2013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2015.04.005</pub-id> <pub-id pub-id-type="pmid">25946646</pub-id></mixed-citation></ref>
<ref id="B5">
<label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spagnolo</surname> <given-names>P</given-names></name> <name><surname>Tzouvelekis</surname> <given-names>A</given-names></name> <name><surname>Bonella</surname> <given-names>F</given-names></name></person-group>. <article-title>The management of patients with idiopathic pulmonary fibrosis.</article-title> <source><italic>Front Med.</italic></source> (<year>2018</year>) <volume>5</volume>:<fpage>148</fpage>. <pub-id pub-id-type="doi">10.3389/fmed.2018.00148</pub-id> <pub-id pub-id-type="pmid">30013972</pub-id></mixed-citation></ref>
<ref id="B6">
<label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gross</surname> <given-names>TJ</given-names></name> <name><surname>Hunninghake</surname> <given-names>GW</given-names></name></person-group>. <article-title>Idiopathic pulmonary fibrosis.</article-title> <source><italic>N Engl J Med.</italic></source> (<year>2001</year>) <volume>345</volume>:<fpage>517</fpage>&#x2013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra003200</pub-id> <pub-id pub-id-type="pmid">11519507</pub-id></mixed-citation></ref>
<ref id="B7">
<label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ley</surname> <given-names>B</given-names></name> <name><surname>Collard</surname> <given-names>HR</given-names></name> <name><surname>King</surname> <given-names>TE</given-names> <suffix>Jr.</suffix></name></person-group> <article-title>Clinical course and prediction of survival in idiopathic pulmonary fibrosis.</article-title> <source><italic>Am J Respir Crit Care Med.</italic></source> (<year>2011</year>) <volume>183</volume>:<fpage>431</fpage>&#x2013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201006-0894CI</pub-id> <pub-id pub-id-type="pmid">20935110</pub-id></mixed-citation></ref>
<ref id="B8">
<label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabrera</surname> <given-names>S</given-names></name> <name><surname>Maciel</surname> <given-names>M</given-names></name> <name><surname>Herrera</surname> <given-names>I</given-names></name> <name><surname>Nava</surname> <given-names>T</given-names></name> <name><surname>Vergara</surname> <given-names>F</given-names></name> <name><surname>Gaxiola</surname> <given-names>M</given-names></name><etal/></person-group> <article-title>Essential role for the ATG4B protease and autophagy in bleomycin-induced pulmonary fibrosis.</article-title> <source><italic>Autophagy.</italic></source> (<year>2015</year>) <volume>11</volume>:<fpage>670</fpage>&#x2013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1080/15548627.2015.1034409</pub-id> <pub-id pub-id-type="pmid">25906080</pub-id></mixed-citation></ref>
<ref id="B9">
<label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname> <given-names>H</given-names></name> <name><surname>Sun</surname> <given-names>J</given-names></name> <name><surname>Zhang</surname> <given-names>S</given-names></name> <name><surname>Nie</surname> <given-names>Y</given-names></name> <name><surname>Zhou</surname> <given-names>S</given-names></name> <name><surname>Zeng</surname> <given-names>Y</given-names></name></person-group>. <article-title>Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies.</article-title> <source><italic>Front Pharmacol.</italic></source> (<year>2023</year>) <volume>14</volume>:<fpage>1205948</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2023.1205948</pub-id> <pub-id pub-id-type="pmid">37608885</pub-id></mixed-citation></ref>
<ref id="B10">
<label>10.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jia</surname> <given-names>S</given-names></name> <name><surname>Kim</surname> <given-names>KK</given-names></name></person-group>. <article-title>The function of epithelial cells in pulmonary fibrosis.</article-title> <source><italic>Lung Epithelial Biology in the Pathogenesis of Pulmonary Disease.</italic></source> <publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier</publisher-name> (<year>2017</year>). p. <fpage>103</fpage>&#x2013;<lpage>31</lpage>.</mixed-citation></ref>
<ref id="B11">
<label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname> <given-names>J</given-names></name> <name><surname>Zhang</surname> <given-names>Y</given-names></name> <name><surname>Xie</surname> <given-names>T</given-names></name> <name><surname>Liu</surname> <given-names>N</given-names></name> <name><surname>Chen</surname> <given-names>H</given-names></name> <name><surname>Geng</surname> <given-names>Y</given-names></name><etal/></person-group> <article-title>Hyaluronan and TLR4 promote surfactant-protein-C-positive alveolar progenitor cell renewal and prevent severe pulmonary fibrosis in mice.</article-title> <source><italic>Nat Med.</italic></source> (<year>2016</year>) <volume>22</volume>:<fpage>1285</fpage>&#x2013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4192</pub-id> <pub-id pub-id-type="pmid">27694932</pub-id></mixed-citation></ref>
<ref id="B12">
<label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname> <given-names>D</given-names></name> <name><surname>Fu</surname> <given-names>M</given-names></name> <name><surname>Wang</surname> <given-names>M</given-names></name> <name><surname>Wei</surname> <given-names>Y</given-names></name> <name><surname>Wei</surname> <given-names>X</given-names></name></person-group>. <article-title>Targeting TGF-&#x03B2; signal transduction for fibrosis and cancer therapy.</article-title> <source><italic>Mol Cancer.</italic></source> (<year>2022</year>) <volume>21</volume>:<fpage>104</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-022-01569-x</pub-id> <pub-id pub-id-type="pmid">35461253</pub-id></mixed-citation></ref>
<ref id="B13">
<label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>J</given-names></name> <name><surname>Pang</surname> <given-names>K</given-names></name> <name><surname>Kim</surname> <given-names>J</given-names></name> <name><surname>Hong</surname> <given-names>E</given-names></name> <name><surname>Lee</surname> <given-names>J</given-names></name> <name><surname>Cho</surname> <given-names>HJ</given-names></name><etal/></person-group> <article-title>ESRP1-regulated isoform switching of LRRFIP2 determines metastasis of gastric cancer.</article-title> <source><italic>Nat Commun.</italic></source> (<year>2022</year>) <volume>13</volume>:<fpage>6274</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-022-33786-9</pub-id> <pub-id pub-id-type="pmid">36307405</pub-id></mixed-citation></ref>
<ref id="B14">
<label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname> <given-names>IM</given-names></name> <name><surname>Cheng</surname> <given-names>AW</given-names></name> <name><surname>Flytzanis</surname> <given-names>NC</given-names></name> <name><surname>Balsamo</surname> <given-names>M</given-names></name> <name><surname>Condeelis</surname> <given-names>JS</given-names></name> <name><surname>Oktay</surname> <given-names>MH</given-names></name><etal/></person-group> <article-title>An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype.</article-title> <source><italic>PLoS Genet.</italic></source> (<year>2011</year>) <volume>7</volume>:<fpage>e1002218</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1002218</pub-id> <pub-id pub-id-type="pmid">21876675</pub-id></mixed-citation></ref>
<ref id="B15">
<label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname> <given-names>G</given-names></name> <name><surname>Zhou</surname> <given-names>X</given-names></name> <name><surname>Chen</surname> <given-names>L</given-names></name> <name><surname>Yao</surname> <given-names>Y</given-names></name> <name><surname>Li</surname> <given-names>J</given-names></name> <name><surname>Zhang</surname> <given-names>Y</given-names></name><etal/></person-group> <article-title>High expression of ESRP1 regulated by circ-0005585 promotes cell colonization in ovarian cancer.</article-title> <source><italic>Cancer Cell Int.</italic></source> (<year>2020</year>) <volume>20</volume>:<fpage>174</fpage>. <pub-id pub-id-type="doi">10.1186/s12935-020-01254-3</pub-id> <pub-id pub-id-type="pmid">32467669</pub-id></mixed-citation></ref>
<ref id="B16">
<label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>J</given-names></name> <name><surname>Li</surname> <given-names>G</given-names></name> <name><surname>Zhang</surname> <given-names>P</given-names></name> <name><surname>Zhuang</surname> <given-names>X</given-names></name> <name><surname>Hu</surname> <given-names>G</given-names></name></person-group>. <article-title>A CD44v(+) subpopulation of breast cancer stem-like cells with enhanced lung metastasis capacity.</article-title> <source><italic>Cell Death Dis.</italic></source> (<year>2017</year>) <volume>8</volume>:<fpage>e2679</fpage>. <pub-id pub-id-type="doi">10.1038/cddis.2017.72</pub-id> <pub-id pub-id-type="pmid">28300837</pub-id></mixed-citation></ref>
<ref id="B17">
<label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname> <given-names>HM</given-names></name> <name><surname>Han</surname> <given-names>J</given-names></name> <name><surname>Lee</surname> <given-names>SH</given-names></name> <name><surname>Park</surname> <given-names>HJ</given-names></name> <name><surname>Lee</surname> <given-names>HJ</given-names></name> <name><surname>Choi</surname> <given-names>JS</given-names></name><etal/></person-group> <article-title>ESRP1 is overexpressed in ovarian cancer and promotes switching from mesenchymal to epithelial phenotype in ovarian cancer cells.</article-title> <source><italic>Oncogenesis.</italic></source> (<year>2017</year>) <volume>6</volume>:<fpage>e389</fpage>. <pub-id pub-id-type="doi">10.1038/oncsis.2017.87</pub-id> <pub-id pub-id-type="pmid">28991261</pub-id></mixed-citation></ref>
<ref id="B18">
<label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>L</given-names></name> <name><surname>Qi</surname> <given-names>L</given-names></name> <name><surname>Qu</surname> <given-names>T</given-names></name> <name><surname>Liu</surname> <given-names>C</given-names></name> <name><surname>Cao</surname> <given-names>L</given-names></name> <name><surname>Huang</surname> <given-names>Q</given-names></name><etal/></person-group> <article-title>Epithelial Splicing Regulatory Protein 1 Inhibits the Invasion and Metastasis of Lung Adenocarcinoma.</article-title> <source><italic>Am J Pathol.</italic></source> (<year>2018</year>) <volume>188</volume>:<fpage>1882</fpage>&#x2013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2018.04.012</pub-id> <pub-id pub-id-type="pmid">29803834</pub-id></mixed-citation></ref>
<ref id="B19">
<label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ueda</surname> <given-names>J</given-names></name> <name><surname>Matsuda</surname> <given-names>Y</given-names></name> <name><surname>Yamahatsu</surname> <given-names>K</given-names></name> <name><surname>Uchida</surname> <given-names>E</given-names></name> <name><surname>Naito</surname> <given-names>Z</given-names></name> <name><surname>Korc</surname> <given-names>M</given-names></name><etal/></person-group> <article-title>Epithelial splicing regulatory protein 1 is a favorable prognostic factor in pancreatic cancer that attenuates pancreatic metastases.</article-title> <source><italic>Oncogene.</italic></source> (<year>2014</year>) <volume>33</volume>:<fpage>4485</fpage>&#x2013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2013.392</pub-id> <pub-id pub-id-type="pmid">24077287</pub-id></mixed-citation></ref>
<ref id="B20">
<label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yae</surname> <given-names>T</given-names></name> <name><surname>Tsuchihashi</surname> <given-names>K</given-names></name> <name><surname>Ishimoto</surname> <given-names>T</given-names></name> <name><surname>Motohara</surname> <given-names>T</given-names></name> <name><surname>Yoshikawa</surname> <given-names>M</given-names></name> <name><surname>Yoshida</surname> <given-names>GJ</given-names></name><etal/></person-group> <article-title>Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell.</article-title> <source><italic>Nat Commun.</italic></source> (<year>2012</year>) <volume>3</volume>:<fpage>883</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms1892</pub-id> <pub-id pub-id-type="pmid">22673910</pub-id></mixed-citation></ref>
<ref id="B21">
<label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>Y</given-names></name> <name><surname>Li</surname> <given-names>M</given-names></name> <name><surname>Wu</surname> <given-names>W</given-names></name> <name><surname>Miao</surname> <given-names>W</given-names></name> <name><surname>Liu</surname> <given-names>H</given-names></name></person-group>. <article-title>Downregulated ESRP1/2 promotes lung metastasis of bladder carcinoma through altering FGFR2 splicing and macrophage polarization.</article-title> <source><italic>Front Immunol.</italic></source> (<year>2023</year>) <volume>14</volume>:<fpage>1161273</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2023.1161273</pub-id> <pub-id pub-id-type="pmid">37090731</pub-id></mixed-citation></ref>
<ref id="B22">
<label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahuja</surname> <given-names>N</given-names></name> <name><surname>Ashok</surname> <given-names>C</given-names></name> <name><surname>Natua</surname> <given-names>S</given-names></name> <name><surname>Pant</surname> <given-names>D</given-names></name> <name><surname>Cherian</surname> <given-names>A</given-names></name> <name><surname>Pandkar</surname> <given-names>MR</given-names></name><etal/></person-group> <article-title>Hypoxia-induced TGF-&#x03B2;-RBFOX2-ESRP1 axis regulates human MENA alternative splicing and promotes EMT in breast cancer.</article-title> <source><italic>NAR Cancer.</italic></source> (<year>2020</year>) <volume>2</volume>:<fpage>zcaa021</fpage>. <pub-id pub-id-type="doi">10.1093/narcan/zcaa021</pub-id> <pub-id pub-id-type="pmid">33089214</pub-id></mixed-citation></ref>
<ref id="B23">
<label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname> <given-names>RL</given-names></name> <name><surname>Reinke</surname> <given-names>LM</given-names></name> <name><surname>Damerow</surname> <given-names>MS</given-names></name> <name><surname>Perez</surname> <given-names>D</given-names></name> <name><surname>Chodosh</surname> <given-names>LA</given-names></name> <name><surname>Yang</surname> <given-names>J</given-names></name><etal/></person-group> <article-title>CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression.</article-title> <source><italic>J Clin Invest.</italic></source> (<year>2011</year>) <volume>121</volume>:<fpage>1064</fpage>&#x2013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1172/jci44540</pub-id> <pub-id pub-id-type="pmid">21393860</pub-id></mixed-citation></ref>
<ref id="B24">
<label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname> <given-names>MJ</given-names></name></person-group>. <article-title>Role of epithelial splicing regulatory protein 1 in cancer progression.</article-title> <source><italic>Cancer Cell Int.</italic></source> (<year>2023</year>) <volume>23</volume>:<fpage>331</fpage>. <pub-id pub-id-type="doi">10.1186/s12935-023-03180-6</pub-id> <pub-id pub-id-type="pmid">38110955</pub-id></mixed-citation></ref>
<ref id="B25">
<label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinke</surname> <given-names>LM</given-names></name> <name><surname>Xu</surname> <given-names>Y</given-names></name> <name><surname>Cheng</surname> <given-names>C</given-names></name></person-group>. <article-title>Snail represses the splicing regulator epithelial splicing regulatory protein 1 to promote epithelial-mesenchymal transition.</article-title> <source><italic>J Biol Chem.</italic></source> (<year>2012</year>) <volume>287</volume>:<fpage>36435</fpage>&#x2013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M112.397125</pub-id> <pub-id pub-id-type="pmid">22961986</pub-id></mixed-citation></ref>
<ref id="B26">
<label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warzecha</surname> <given-names>CC</given-names></name> <name><surname>Jiang</surname> <given-names>P</given-names></name> <name><surname>Amirikian</surname> <given-names>K</given-names></name> <name><surname>Dittmar</surname> <given-names>KA</given-names></name> <name><surname>Lu</surname> <given-names>H</given-names></name> <name><surname>Shen</surname> <given-names>S</given-names></name><etal/></person-group> <article-title>An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition.</article-title> <source><italic>EMBO J.</italic></source> (<year>2010</year>) <volume>29</volume>:<fpage>3286</fpage>&#x2013;<lpage>300</lpage>. <pub-id pub-id-type="doi">10.1038/emboj.2010.195</pub-id> <pub-id pub-id-type="pmid">20711167</pub-id></mixed-citation></ref>
<ref id="B27">
<label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warzecha</surname> <given-names>CC</given-names></name> <name><surname>Sato</surname> <given-names>TK</given-names></name> <name><surname>Nabet</surname> <given-names>B</given-names></name> <name><surname>Hogenesch</surname> <given-names>JB</given-names></name> <name><surname>Carstens</surname> <given-names>RP</given-names></name></person-group>. <article-title>ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing.</article-title> <source><italic>Mol Cell.</italic></source> (<year>2009</year>) <volume>33</volume>:<fpage>591</fpage>&#x2013;<lpage>601</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2009.01.025</pub-id> <pub-id pub-id-type="pmid">19285943</pub-id></mixed-citation></ref>
<ref id="B28">
<label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname> <given-names>K</given-names></name> <name><surname>He</surname> <given-names>B</given-names></name> <name><surname>Yang</surname> <given-names>BB</given-names></name> <name><surname>Xu</surname> <given-names>T</given-names></name> <name><surname>Chen</surname> <given-names>X</given-names></name> <name><surname>Xu</surname> <given-names>M</given-names></name><etal/></person-group> <article-title>The pro-metastasis effect of circANKS1B in breast cancer.</article-title> <source><italic>Mol Cancer.</italic></source> (<year>2018</year>) <volume>17</volume>:<fpage>160</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-018-0914-x</pub-id> <pub-id pub-id-type="pmid">30454010</pub-id></mixed-citation></ref>
<ref id="B29">
<label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>YY</given-names></name> <name><surname>Murai</surname> <given-names>K</given-names></name> <name><surname>Lyu</surname> <given-names>J</given-names></name> <name><surname>Honda</surname> <given-names>M</given-names></name></person-group>. <article-title>Roles played by DOCK11, a guanine nucleotide exchange factor, in HBV entry and persistence in hepatocytes.</article-title> <source><italic>Viruses.</italic></source> (<year>2024</year>) <volume>16</volume>:<fpage>745</fpage>. <pub-id pub-id-type="doi">10.3390/v16050745</pub-id> <pub-id pub-id-type="pmid">38793626</pub-id></mixed-citation></ref>
<ref id="B30">
<label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ja&#x015B;kiewicz</surname> <given-names>A</given-names></name> <name><surname>Paj&#x0105;k</surname> <given-names>B</given-names></name> <name><surname>Orzechowski</surname> <given-names>A</given-names></name></person-group>. <article-title>The Many Faces of Rap1 GTPase.</article-title> <source><italic>Intern J Mol Sci.</italic></source> (<year>2018</year>) <volume>19</volume>:<fpage>2848</fpage>. <pub-id pub-id-type="doi">10.3390/ijms19102848</pub-id> <pub-id pub-id-type="pmid">30241315</pub-id></mixed-citation></ref>
<ref id="B31">
<label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lagarrigue</surname> <given-names>F</given-names></name> <name><surname>Kim</surname> <given-names>C</given-names></name> <name><surname>Ginsberg</surname> <given-names>MH</given-names></name></person-group>. <article-title>The Rap1-RIAM-talin axis of integrin activation and blood cell function.</article-title> <source><italic>Blood.</italic></source> (<year>2016</year>) <volume>128</volume>:<fpage>479</fpage>&#x2013;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2015-12-638700</pub-id> <pub-id pub-id-type="pmid">27207789</pub-id></mixed-citation></ref>
<ref id="B32">
<label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>K</given-names></name></person-group>. <article-title>Epac: new emerging cAMP-binding protein.</article-title> <source><italic>BMB Rep.</italic></source> (<year>2021</year>) <volume>54</volume>:<fpage>149</fpage>&#x2013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.5483/BMBRep.2021.54.3.233</pub-id> <pub-id pub-id-type="pmid">33298248</pub-id></mixed-citation></ref>
<ref id="B33">
<label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname> <given-names>F</given-names></name> <name><surname>Lungu</surname> <given-names>C</given-names></name> <name><surname>Noll</surname> <given-names>B</given-names></name> <name><surname>Benz</surname> <given-names>D</given-names></name> <name><surname>Fr&#x00E4;nkle</surname> <given-names>F</given-names></name> <name><surname>Ferreira</surname> <given-names>M</given-names></name><etal/></person-group> <article-title>Reciprocal regulation of Solo and SRC orchestrates SRC trafficking to promote mesenchymal cell migration.</article-title> <source><italic>iScience.</italic></source> (<year>2025</year>) <volume>28</volume>:<fpage>112618</fpage>. <pub-id pub-id-type="doi">10.1016/j.isci.2025.112618</pub-id> <pub-id pub-id-type="pmid">40502686</pub-id></mixed-citation></ref>
<ref id="B34">
<label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridley</surname> <given-names>AJ</given-names></name></person-group>. <article-title>Rho GTPases and cell migration.</article-title> <source><italic>J Cell Sci.</italic></source> (<year>2001</year>) <volume>114</volume>:<fpage>2713</fpage>&#x2013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.114.15.2713</pub-id> <pub-id pub-id-type="pmid">11683406</pub-id></mixed-citation></ref>
<ref id="B35">
<label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>J</given-names></name> <name><surname>Randive</surname> <given-names>R</given-names></name> <name><surname>Stewart</surname> <given-names>JA</given-names></name></person-group>. <article-title>Molecular mechanisms of AGE/RAGE-mediated fibrosis in the diabetic heart.</article-title> <source><italic>World J Diab.</italic></source> (<year>2014</year>) <volume>5</volume>:<fpage>860</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.4239/wjd.v5.i6.860</pub-id> <pub-id pub-id-type="pmid">25512788</pub-id></mixed-citation></ref>
<ref id="B36">
<label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burckhardt</surname> <given-names>CJ</given-names></name> <name><surname>Minna</surname> <given-names>JD</given-names></name> <name><surname>Danuser</surname> <given-names>G</given-names></name></person-group>. <article-title>Co-immunoprecipitation and semi-quantitative immunoblotting for the analysis of protein-protein interactions.</article-title> <source><italic>STAR Protoc.</italic></source> (<year>2021</year>) <volume>2</volume>:<fpage>100644</fpage>. <pub-id pub-id-type="doi">10.1016/j.xpro.2021.100644</pub-id> <pub-id pub-id-type="pmid">34278331</pub-id></mixed-citation></ref>
<ref id="B37">
<label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burckhardt</surname> <given-names>CJ</given-names></name> <name><surname>Minna</surname> <given-names>JD</given-names></name> <name><surname>Danuser</surname> <given-names>G</given-names></name></person-group>. <article-title>SH3BP4 promotes neuropilin-1 and &#x03B1;5-integrin endocytosis and is inhibited by Akt.</article-title> <source><italic>Dev Cell.</italic></source> (<year>2021</year>) <volume>56</volume>: <fpage>1164</fpage>&#x2013;<lpage>81.e12</lpage>. <pub-id pub-id-type="doi">10.1016/j.devcel.2021.03.009</pub-id> <pub-id pub-id-type="pmid">33761321</pub-id></mixed-citation></ref>
</ref-list>
<fn-group>
<fn id="n1" fn-type="custom" custom-type="edited-by"><p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/59155/overview">Venkaiah Betapudi</ext-link>, United States Department of Health and Human Services, United States</p></fn>
<fn id="n2" fn-type="custom" custom-type="reviewed-by"><p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2724913/overview">Junxiang Huang</ext-link>, Boston College, United States</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3272717/overview">Zongbo Wei</ext-link>, Augusta University, United States</p></fn>
</fn-group>
<fn-group>
<fn fn-type="abbr" id="abbrev1">
<label>Abbreviations:</label><p>ESRP1, Epithelial splicing regulatory protein 1; EMT, Epithelial-mesenchymal transition; IPF, Idiopathic pulmonary fibrosis; BLM, bleomycin; scRNA-seq, single-cell RNA sequencing; TGF-&#x03B2;<sub>1</sub>, Transforming Growth Factor-beta 1; ECM, extracellular matrix; E-cad, E-cadherin; &#x03B1;-SMA, alpha-Smooth Muscle Actin; 1ZO-1, Zonula Occludens-1; bFGF, basic Fibroblast Growth Factor; FGFR2, Fibroblast Growth Factor Receptor 2; CD44, Cluster of Differentiation 44; CTNND1, Catenin Delta 1, (p120-catenin); ENAH, Enabled Homolog; Vim, Vimentin; Epac, Exchange Protein directly Activated by cAMP; Rap1a, Ras-related Protein 1a; Fn1, Fibronectin; Zeb1, Zinc Finger E-box Binding Homeobox 1; DCs, Dendritic Cells; Col1a1, Collagen Type I Alpha 1; Acta2, Actin Alpha 2, Smooth Muscle; UMAP, Uniform Manifold Approximation and Projection; PBS, Phosphate-Buffered Saline; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; RAP, Ras-related Protein; GEFs, Guanine nucleotide exchange factors; Epcam, Epithelial Cell Adhesion Molecule; MLE-12, mouse lung epithelial cells; IF, Immunofluorescence; Co-IP, Co-Immunoprecipitation; HRCT, High-Resolution Computed Tomography; ATS, the American Thoracic Society; ERS, the European Respiratory Society; HC, Healthy Control; H&#x0026;E, hematoxylin and eosin; ABC, streptavidin-biotin complex; DAB, 3,3&#x2019;-Diaminobenzidine Tetrahydrochloride; DAPI,4&#x2019;,6-Diamidino-2-Phenylindole, Dihydrochloride; ELISA, Enzyme-Linked Immunosorbent Assay.</p></fn>
</fn-group>
</back>
</article>